Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy-Reference-Cited by-同舟云学术

Pharmacology, pharmacokinetics, and toxicity characterization of a novel anti-CD73 therapeutic antibody IBI325 for cancer immunotherapy

Published:2023-02 Issue: Volume:229 Page:158-167
ISSN:0141-8130
Container-title:International Journal of Biological Macromolecules
language:en
Short-container-title:International Journal of Biological Macromolecules

Author:

Zhou Ying,Shen Haoran,Wu Min,Wang Jie,Wu Zhihai,Fu Fenggen,Liu Yang,Lu Jia,Yao Ying,Luo Nana,Zhou Shuaixiang,Tan Keai Sinn,Chen Bingliang,Wang Dongfang

Publisher

Elsevier BV

Subject

Molecular Biology,General Medicine,Biochemistry,Structural Biology

Reference30 articles.

1. A guide to cancer immunotherapy: from T cell basic science to clinical practice;Waldman;Nat. Rev. Immunol.,2020

2. Immune escape mechanisms as a guide for cancer immunotherapy;Beatty;Clin. Cancer Res.,2015

3. Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape;Upadhaya;Nat. Rev. Drug Discov.,2022

4. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action;Geoghegan;MAbs,2016

5. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial;Buisseret;Ann. Oncol.,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD19+CD73+ B cells infiltration indicates poor prognosis and unfavorable responses to immunotherapy in gastric cancer;International Immunopharmacology;2024-11

2. The Clinical Significance of CD73 in Cancer;International Journal of Molecular Sciences;2023-07-21